Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease (CKD) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00985426
Recruitment Status : Completed
First Posted : September 28, 2009
Last Update Posted : February 22, 2018
Information provided by (Responsible Party):
Dynavax Technologies Corporation

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : January 2012
  Actual Study Completion Date : January 2012
  Certification/Extension First Submitted : June 16, 2014